

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

Aukunuru, Jithan et al.

Examiner: Basquill, Sean M.

INTERNATIONAL APPLICATION NO: PCT/EP03/08005

FILED: July 22, 2003

U.S. APPLICATION NO: 10/521946

35 USC §371 DATE: January 21, 2005

FOR: Ophthalmic Ointment Comprising a Drug, an Ointment
Base and a Solubilizing/Dispersing Agent

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587
Date: